US 11,857,680 B2
Composition of docetaxel liposomal injection with high drug loading
Kiran K Jadhav, Bangalore (IN); Prashanth S, Bangalore (IN); Shivakumar Pradeep, Visianagaram (IN); and Sreenivasa Reddy, Bangalore (IN)
Assigned to SHILPA MEDICARE LIMITED, Kamataka (IN)
Filed by SHILPA MEDICARE LIMITED, Raichur (IN)
Filed on Oct. 19, 2020, as Appl. No. 17/073,437.
Application 17/073,437 is a continuation of application No. 16/480,308, previously published as PCT/IB2018/059280, filed on Nov. 26, 2018.
Prior Publication US 2022/0117892 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 31/337 (2006.01); A61K 47/26 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1277 (2013.01); A61K 31/337 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/28 (2013.01)] 5 Claims
 
1. A pharmaceutical liposomal composition consisting of comprising
(a) about 0.8% w/w to about 1% w/w of docetaxel,
(b) about 30% w/w to about 38% w/w of Soya Phosphatidyl Choline,
(c) about 0.2% w/w to about 0.8% w/w of Sodium Cholesteryl Sulfate,
(d) about 61% w/w to about 68% w/w of Sucrose and
(e) a pH adjusting agent,
wherein the pH of liposomal composition is less than 3.5 and wherein the liposomal composition is prepared by a process of dispersing Soya Phosphatidyl Choline in solvent mixture of methanol and tertiary butanol in the ratio of 1:1.